<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> is characterized by mild unconjugated nonhemolytic <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, without <z:mp ids='MP_0001860'>hepatic inflammation</z:mp>, <z:mp ids='MP_0003045'>fibrosis</z:mp>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e>, or <z:hpo ids='HP_0001399'>liver failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is readily diagnosed by genetic variants of the UGT1A1 gene, mainly UGT1A1*28, and is also associated with abnormalities of hepatobiliary transport and additional UGT1A gene variants </plain></SENT>
<SENT sid="2" pm="."><plain>Apart from representing a potential risk factor in irinotecan and <z:chebi fb="0" ids="37670">protease inhibitor</z:chebi> therapy, it appears to exert protective effects in Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> is part of a continuous spectrum of altered glucuronidation that extends to fatal Crigler-najjar disease </plain></SENT>
<SENT sid="4" pm="."><plain>The complexity hidden behind this pharmacogenetic abnormality is of profound significance for drug development and therapy </plain></SENT>
</text></document>